Gilead (NASDAQ:GILD) will be reporting 4Q earnings on Monday, as well as the company's full 2012 results. In this video, Motley Fool health-care analyst David Williamson tells us why it has been a transformational year for the company, and what  key things to watch for in the upcoming earnings report.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.